AstraZeneca FY2025 EPS Estimate Raised by Zacks Research

AstraZeneca PLC (NASDAQ:AZN) – Equities research analysts at Zacks Research boosted their FY2025 earnings per share (EPS) estimates for AstraZeneca in a research note issued to investors on Monday, February 3rd. Zacks Research analyst R. Department now anticipates that the company will earn $4.59 per share for the year, up from their previous forecast of $4.58. The consensus estimate for AstraZeneca’s current full-year earnings is $4.13 per share. Zacks Research also issued estimates for AstraZeneca’s Q4 2026 earnings at $1.35 EPS and FY2026 earnings at $5.09 EPS.

AZN has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Stock Performance

Shares of AstraZeneca stock opened at $68.96 on Wednesday. The business has a 50-day moving average price of $67.20 and a two-hundred day moving average price of $73.72. AstraZeneca has a 1-year low of $60.47 and a 1-year high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The company has a market cap of $213.85 billion, a P/E ratio of 33.00, a PEG ratio of 1.18 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the previous year, the company earned $0.87 EPS. The company’s revenue for the quarter was up 18.0% on a year-over-year basis.

Hedge Funds Weigh In On AstraZeneca

A number of large investors have recently modified their holdings of the company. McClarren Financial Advisors Inc. lifted its holdings in shares of AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares in the last quarter. Capital Performance Advisors LLP bought a new position in AstraZeneca during the 3rd quarter valued at $28,000. Albion Financial Group UT lifted its stake in AstraZeneca by 68.9% during the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after acquiring an additional 248 shares in the last quarter. Groupama Asset Managment grew its stake in shares of AstraZeneca by 22.9% in the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after acquiring an additional 101,225 shares in the last quarter. Finally, Ashton Thomas Securities LLC purchased a new stake in shares of AstraZeneca in the third quarter valued at about $45,000. 20.35% of the stock is currently owned by institutional investors.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.